Zilver PTX Post-market Surveillance Study of Paclitaxel-Eluting Stents for Treating Femoropopliteal Artery Disease in Japan: 2-Year Results-Reference-Cited by-同舟云学术

Zilver PTX Post-market Surveillance Study of Paclitaxel-Eluting Stents for Treating Femoropopliteal Artery Disease in Japan: 2-Year Results

Published:2018-11-08 Issue:3 Volume:42 Page:358-364
ISSN:0174-1551
Container-title:CardioVascular and Interventional Radiology
language:en
Short-container-title:Cardiovasc Intervent Radiol

Author:

Kichikawa Kimihiko,Ichihashi Shigeo^ORCID,Yokoi Hiroyoshi,Ohki Takao,Nakamura Masato,Komori Kimihiro,Nanto Shinsuke,O’Leary Erin E.,Lottes Aaron E.,Snyder Scott A.,Dake Michael D.

Funder

Cook Medical

Publisher

Springer Science and Business Media LLC

Subject

Cardiology and Cardiovascular Medicine,Radiology Nuclear Medicine and imaging

Link

http://link.springer.com/article/10.1007/s00270-018-2110-1/fulltext.html

Reference18 articles.

1. Dearing DD, Patel KR, Compoginis JM, Kamel MA, Weaver FA, Katz SG. Primary stenting of the superficial femoral and popliteal artery. J Vasc Surg. 2009;50(3):542–7. https://doi.org/10.1016/j.jvs.2009.04.019 .

2. Iida O, Takahara M, Soga Y, Suzuki K, Hirano K, Kawasaki D, et al. Shared and differential factors influencing restenosis following endovascular therapy between TASC (Trans-Atlantic Inter-Society Consensus) II class A to C and D lesions in the femoropopliteal artery. J Am Coll Cardiol Interv. 2014;7(7):792–8. https://doi.org/10.1016/j.jcin.2014.01.168 .

3. Stavroulakis K, Torsello G, Manal A, Schwindt A, Hericks C, Stachmann A, et al. Results of primary stent therapy for femoropopliteal peripheral arterial disease at 7 years. J Vasc Surg. 2016;64(6):1696–702. https://doi.org/10.1016/j.jvs.2016.05.073 .

4. Yokoi H, Ohki T, Kichikawa K, Nakamura M, Komori K, Nanto S, et al. Zilver PTX post-market surveillance study of paclitaxel-eluting stents for treating femoropopliteal artery disease in Japan: 12-month results. J Am Coll Cardiol Interv. 2016;9(3):271–7. https://doi.org/10.1016/j.jcin.2015.09.035 .

5. Dake MD, Ansel GM, Jaff MR, Ohki T, Saxon RR, Smouse HB, et al. Paclitaxel-eluting stents show superiority to balloon angioplasty and bare metal stents in femoropopliteal disease: twelve-month Zilver PTX randomized study results. Circ Cardiovasc Interv. 2011;4(5):495–504. https://doi.org/10.1161/circinterventions.111.962324 .

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Duplex Ultrasound Surveillance After Femoropopliteal Endovascular Treatment for Peripheral Arterial Disease: A Systematic Review and Narrative Synthesis;Annals of Vascular Surgery;2024-07

2. Is Calcium the Natural Enemy of Drug-Eluting Therapy?;CardioVascular and Interventional Radiology;2024-04-01

3. Korean Multicenter Registry of ELUVIA Stent for Femoropopliteal Artery Disease: K-ELUVIA Registry;Korean Circulation Journal;2024

4. Long-Term Patient Outcomes After Femoropopliteal Peripheral Vascular Intervention in Patients With Intermittent Claudication;JACC: Cardiovascular Interventions;2023-07

5. One Year Outcomes of Zilver PTX Versus Eluvia for Femoropopliteal Disease in Real-World Practice: REALDES Study;Journal of Endovascular Therapy;2023-06-08